← All trials
NCT01231113
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Dec 1, 2012
- Completion date
- Feb 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 417
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Kwame Nkrumah University of Science and TechnologyLead sponsor
- Kwame Nkrumah University of Science and TechnologyStudy director
- University of CopenhagenStudy director
- Malaria Capacity Development ConsortiumCollaborator
- Kwame Nkrumah University of Science and TechnologyReponsible party - principal investigator
- Kwame Nkrumah University of Science and TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.